Press coverage about Radius Health (NASDAQ:RDUS) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Radius Health earned a news impact score of 0.10 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.3145367970019 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of analysts have recently weighed in on the company. Morgan Stanley assumed coverage on Radius Health in a research report on Monday, January 29th. They set an “overweight” rating and a $57.00 target price for the company. Citigroup reiterated a “hold” rating and issued a $43.00 target price on shares of Radius Health in a research report on Monday, January 22nd. Cantor Fitzgerald reissued a “buy” rating and issued a $58.00 price target on shares of Radius Health in a research note on Thursday, January 18th. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Finally, Zacks Investment Research raised Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, January 8th. One investment analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company. Radius Health currently has an average rating of “Hold” and an average price target of $50.75.
Shares of Radius Health (RDUS) traded up $0.12 during mid-day trading on Friday, reaching $33.62. The company’s stock had a trading volume of 167,106 shares, compared to its average volume of 879,863. The company has a debt-to-equity ratio of 0.53, a quick ratio of 12.79 and a current ratio of 12.87. Radius Health has a 52-week low of $24.66 and a 52-week high of $49.16. The company has a market capitalization of $1,613.78, a price-to-earnings ratio of -6.17 and a beta of 1.21.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/02/09/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-radius-health-rdus-share-price.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.